메뉴 건너뛰기




Volumn 140, Issue 21, 2019, Pages 1693-1702

Effect of Empagliflozin on Left Ventricular Mass in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial

(19)  Verma, Subodh a,b,c   Mazer, C David a,b,c   Yan, Andrew T a,b,c   Mason, Tamique a,c   Garg, Vinay a,b,c   Teoh, Hwee a   Zuo, Fei a   Quan, Adrian a   Farkouh, Michael E b,c,e   Fitchett, David H a   Goodman, Shaun G a,b,f,g   Goldenberg, Ronald M h,i   Al Omran, Mohammed a,b,c   Gilbert, Richard E a   Bhatt, Deepak L i   Leiter, Lawrence A a,b,c   Jüni, Peter a,b,d   Zinman, Bernard b,j   Connelly, Kim A a,b,c  


Author keywords

coronary artery disease; diabetes mellitus; SGLT2 inhibitors; ventricular myocardium

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EMPAGLIFLOZIN; GLYCOSYLATED HEMOGLOBIN; INSULIN; METFORMIN; PLACEBO; BENZHYDRYL DERIVATIVE; GLUCOSIDE;

EID: 85075206104     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.119.042375     Document Type: Article
Times cited : (413)

References (33)
  • 4
    • 85034212680 scopus 로고    scopus 로고
    • Cardiovascular outcomes and safety of empagliflozin in patients with type 2 diabetes mellitus and peripheral artery disease: A subanalysis of EMPA-REG OUTCOME
    • Verma S, Mazer CD, Al-Omran M, Inzucchi SE, Fitchett D, Hehnke U, George JT, Zinman B, Cardiovascular outcomes and safety of empagliflozin in patients with type 2 diabetes mellitus and peripheral artery disease: a subanalysis of EMPA-REG OUTCOME. Circulation 2018 137 405 407. doi: 10.1161/CIRCULATIONAHA.117.032031
    • (2018) Circulation , vol.137 , pp. 405-407
    • Verma, S.1    Mazer, C.D.2    Al-Omran, M.3    Inzucchi, S.E.4    Fitchett, D.5    Hehnke, U.6    George, J.T.7    Zinman, B.8
  • 5
    • 85047121888 scopus 로고    scopus 로고
    • Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: Subanalysis of the EMPA-REG OUTCOME® randomised trial
    • Verma S, Mazer CD, Fitchett D, Inzucchi SE, Pfarr E, George JT, Zinman B, Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial. Diabetologia 2018 61 1712 1723. doi: 10.1007/s00125-018-4644-9
    • (2018) Diabetologia , vol.61 , pp. 1712-1723
    • Verma, S.1    Mazer, C.D.2    Fitchett, D.3    Inzucchi, S.E.4    Pfarr, E.5    George, J.T.6    Zinman, B.7
  • 7
    • 85030655315 scopus 로고    scopus 로고
    • The metabolodiuretic promise of sodium-dependent glucose cotransporter 2 inhibition: The search for the sweet spot in heart failure
    • Verma S, McMurray JJV, Cherney DZI, The metabolodiuretic promise of sodium-dependent glucose cotransporter 2 inhibition: the search for the sweet spot in heart failure. JAMA Cardiol 2017 2 939 940. doi: 10.1001/jamacardio.2017.1891
    • (2017) JAMA Cardiol , vol.2 , pp. 939-940
    • Verma, S.1    McMurray, J.J.V.2    Cherney, D.Z.I.3
  • 8
    • 85060373069 scopus 로고    scopus 로고
    • Potential mechanisms underlying the cardiovascular benefits of sodium glucose cotransporter 2 inhibitors: A systematic review of data from preclinical studies
    • Chin KL, Ofori-Asenso R, Hopper I, von Lueder TG, Reid CM, Zoungas S, Wang BH, Liew D, Potential mechanisms underlying the cardiovascular benefits of sodium glucose cotransporter 2 inhibitors: a systematic review of data from preclinical studies. Cardiovasc Res 2019 115 266 276. doi: 10.1093/cvr/cvy295
    • (2019) Cardiovasc Res , vol.115 , pp. 266-276
    • Chin, K.L.1    Ofori-Asenso, R.2    Hopper, I.3    Von Lueder, T.G.4    Reid, C.M.5    Zoungas, S.6    Wang, B.H.7    Liew, D.8
  • 9
    • 85052558182 scopus 로고    scopus 로고
    • SGLT2 inhibitors and mechanisms of cardiovascular benefit: A state-of-the-art review
    • Verma S, McMurray JJV, SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia 2018 61 2108 2117. doi: 10.1007/s00125-018-4670-7
    • (2018) Diabetologia , vol.61 , pp. 2108-2117
    • Verma, S.1    McMurray, J.J.V.2
  • 10
    • 0032212316 scopus 로고    scopus 로고
    • Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death
    • Haider AW, Larson MG, Benjamin EJ, Levy D, Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol 1998 32 1454 1459. doi: 10.1016/s0735-1097(98)00407-0
    • (1998) J Am Coll Cardiol , vol.32 , pp. 1454-1459
    • Haider, A.W.1    Larson, M.G.2    Benjamin, E.J.3    Levy, D.4
  • 11
    • 57449107274 scopus 로고    scopus 로고
    • The relationship of left ventricular mass and geometry to incident cardiovascular events: The MESA (Multi-Ethnic Study of Atherosclerosis) study
    • Bluemke DA, Kronmal RA, Lima JA, Liu K, Olson J, Burke GL, Folsom AR, The relationship of left ventricular mass and geometry to incident cardiovascular events: the MESA (Multi-Ethnic Study of Atherosclerosis) study. J Am Coll Cardiol 2008 52 2148 2155. doi: 10.1016/j.jacc.2008.09.014
    • (2008) J Am Coll Cardiol , vol.52 , pp. 2148-2155
    • Bluemke, D.A.1    Kronmal, R.A.2    Lima, J.A.3    Liu, K.4    Olson, J.5    Burke, G.L.6    Folsom, A.R.7
  • 12
    • 0026092229 scopus 로고
    • Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension
    • Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH, Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991 114 345 352. doi: 10.7326/0003-4819-114-5-345
    • (1991) Ann Intern Med , vol.114 , pp. 345-352
    • Koren, M.J.1    Devereux, R.B.2    Casale, P.N.3    Savage, D.D.4    Laragh, J.H.5
  • 14
    • 0035797832 scopus 로고    scopus 로고
    • Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril
    • Mathew J, Sleight P, Lonn E, Johnstone D, Pogue J, Yi Q, Bosch J, Sussex B, Probstfield J, Yusuf S, Heart Outcomes Prevention Evaluation (HOPE) Investigators Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 2001 104 1615 1621. doi: 10.1161/hc3901.096700
    • (2001) Circulation , vol.104 , pp. 1615-1621
    • Mathew, J.1    Sleight, P.2    Lonn, E.3    Johnstone, D.4    Pogue, J.5    Yi, Q.6    Bosch, J.7    Sussex, B.8    Probstfield, J.9    Yusuf, S.10
  • 15
    • 4544269713 scopus 로고    scopus 로고
    • Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial
    • Devereux RB, Dahlöf B, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris KE, Edelman JM, Wachtell K, Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 2004 110 1456 1462. doi: 10.1161/01.CIR.0000141573.44737.5A
    • (2004) Circulation , vol.110 , pp. 1456-1462
    • Devereux, R.B.1    Dahlöf, B.2    Gerdts, E.3    Boman, K.4    Nieminen, M.S.5    Papademetriou, V.6    Rokkedal, J.7    Harris, K.E.8    Edelman, J.M.9    Wachtell, K.10
  • 21
    • 85056869824 scopus 로고    scopus 로고
    • Can we DECLARE a victory against cardio-renal disease in diabetes?
    • Connelly KA, Bhatt DL, Verma S, Can we DECLARE a victory against cardio-renal disease in diabetes? Cell Metab 2018 28 813 815. doi: 10.1016/j.cmet.2018.11.010
    • (2018) Cell Metab , vol.28 , pp. 813-815
    • Connelly, K.A.1    Bhatt, D.L.2    Verma, S.3
  • 22
    • 84991106931 scopus 로고    scopus 로고
    • Empagliflozin's fuel hypothesis: Not so soon
    • Lopaschuk GD, Verma S, Empagliflozin's fuel hypothesis: not so soon. Cell Metab 2016 24 200 202. doi: 10.1016/j.cmet.2016.07.018
    • (2016) Cell Metab , vol.24 , pp. 200-202
    • Lopaschuk, G.D.1    Verma, S.2
  • 23
    • 85006172812 scopus 로고    scopus 로고
    • Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: An important clue to the EMPA-REG OUTCOME trial?
    • Verma S, Garg A, Yan AT, Gupta AK, Al-Omran M, Sabongui A, Teoh H, Mazer CD, Connelly KA, Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an important clue to the EMPA-REG OUTCOME trial? Diabetes Care 2016 39 e212 e213. doi: 10.2337/dc16-1312
    • (2016) Diabetes Care , vol.39 , pp. e212-e213
    • Verma, S.1    Garg, A.2    Yan, A.T.3    Gupta, A.K.4    Al-Omran, M.5    Sabongui, A.6    Teoh, H.7    Mazer, C.D.8    Connelly, K.A.9
  • 25
    • 85073678741 scopus 로고    scopus 로고
    • 24-hour blood pressure-lowering effect of an SGLT-2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: Results from the randomized, placebo-controlled SACRA study
    • Kario K, Okada K, Kato M, Nishizawa M, Yoshida T, Asano T, Uchiyama K, Niijima Y, Katsuya T, Urata H, 24-hour blood pressure-lowering effect of an SGLT-2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: results from the randomized, placebo-controlled SACRA study. Circulation 2019 139 2089 2097. doi: 10.1161/CIRCULATIONAHA.118.037076
    • (2019) Circulation , vol.139 , pp. 2089-2097
    • Kario, K.1    Okada, K.2    Kato, M.3    Nishizawa, M.4    Yoshida, T.5    Asano, T.6    Uchiyama, K.7    Niijima, Y.8    Katsuya, T.9    Urata, H.10
  • 26
    • 85015822587 scopus 로고    scopus 로고
    • Real role of β-blockers in regression of left ventricular mass in hypertension patients: Bayesian network meta-analysis
    • Xing F, Chen J, Zhao B, Jiang J, Tang A, Chen Y, Real role of β-blockers in regression of left ventricular mass in hypertension patients: Bayesian network meta-analysis. Medicine (Baltimore) 2017 96 e6290. doi: 10.1097/MD.0000000000006290
    • (2017) Medicine (Baltimore) , vol.96 , pp. e6290
    • Xing, F.1    Chen, J.2    Zhao, B.3    Jiang, J.4    Tang, A.5    Chen, Y.6
  • 27
    • 85045943801 scopus 로고    scopus 로고
    • The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: The results of a randomized, double-blind, active-controlled study
    • Schmieder RE, Wagner F, Mayr M, Delles C, Ott C, Keicher C, Hrabak-Paar M, Heye T, Aichner S, Khder Y, The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study. Eur Heart J 2017 38 3308 3317. doi: 10.1093/eurheartj/ehx525
    • (2017) Eur Heart J , vol.38 , pp. 3308-3317
    • Schmieder, R.E.1    Wagner, F.2    Mayr, M.3    Delles, C.4    Ott, C.5    Keicher, C.6    Hrabak-Paar, M.7    Heye, T.8    Aichner, S.9    Khder, Y.10
  • 28
    • 85061917506 scopus 로고    scopus 로고
    • Empagliflozin and cardiovascular outcomes in patients with type 2 diabetes and left ventricular hypertrophy: A subanalysis of the EMPA-REG OUTCOME trial
    • Verma S, Mazer CD, Bhatt DL, Raj SR, Yan AT, Verma A, Ferrannini E, Simons G, Lee J, Zinman B, Empagliflozin and cardiovascular outcomes in patients with type 2 diabetes and left ventricular hypertrophy: a subanalysis of the EMPA-REG OUTCOME trial. Diabetes Care 2019 42 e42 e44. doi: 10.2337/dc18-1959
    • (2019) Diabetes Care , vol.42 , pp. e42-e44
    • Verma, S.1    Mazer, C.D.2    Bhatt, D.L.3    Raj, S.R.4    Yan, A.T.5    Verma, A.6    Ferrannini, E.7    Simons, G.8    Lee, J.9    Zinman, B.10
  • 31
  • 33
    • 85067270152 scopus 로고    scopus 로고
    • The serendipitous story of SGLT2 inhibitors in heart failure
    • Verma S, McMurray JJV, The serendipitous story of SGLT2 inhibitors in heart failure. Circulation 2019 139 2537 2541. doi: 10.1161/CIRCULATIONAHA.119.040514
    • (2019) Circulation , vol.139 , pp. 2537-2541
    • Verma, S.1    McMurray, J.J.V.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.